Bryce Norman, PA
Physician Assistant · Watsontown, PANPI 1669082541
Payments from drug & device makers
Across 738 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Amgen$779
- AstraZeneca$762
- Pfizer$659
- plus $4K from 31 others
What the payments were for
- Food & beverage$11,954100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 131 | $2,121 |
| Novo Nordisk | 119 | $1,822 |
| Lilly USA, LLC | 110 | $1,534 |
| Amgen | 53 | $779 |
| AstraZeneca(2 entities) | 32 | $762 |
| Pfizer | 44 | $659 |
| GSK | 38 | $648 |
| Astellas Pharma US Inc | 22 | $483 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $461 |
| Merck | 27 | $381 |
| Exact Sciences | 14 | $316 |
| Phathom Pharmaceuticals, Inc. | 10 | $235 |
| Novartis | 12 | $209 |
| Johnson & Johnson | 14 | $205 |
| Boehringer Ingelheim | 16 | $196 |
| Bayer | 9 | $156 |
| Otsuka America Pharmaceutical, Inc. | 6 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $118 |
| Teva Pharmaceuticals USA, Inc. | 6 | $102 |
| Dexcom, Inc. | 5 | $93 |
| Esperion Therapeutics, Inc. | 5 | $92 |
| Organon | 5 | $64 |
| Cequr Corporation | 2 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| Genentech USA, Inc. | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| IBSA Pharma Inc. | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Biogen | 2 | $27 |
| Corium, LLC | 2 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Indivior Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Neurelis, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,000 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 262 | $257,987 |
| JardianceEmpagliflozin | 205 | $242,599 |
| OzempicSemaglutide | 143 | $213,631 |
| ProliaDenosumab | 62 | $106,225 |
| MyrbetriqMirabegron | 129 | $90,850 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $84,546 |
| TrulicityDulaglutide | 68 | $82,335 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $40,836 |
| RybelsusSemaglutide | 37 | $40,385 |
| XareltoRivaroxaban | 35 | $37,376 |
| MounjaroTirzepatide | 28 | $34,701 |
| FarxigaDapagliflozin Propanediol | 28 | $28,216 |
| JanuviaSitagliptin Phosphate | 20 | $28,036 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $27,297 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $20,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $196 | $260,415232 claims |
| PfizerEliquis | $659 | $257,987262 claims |
| Novo NordiskOzempic, Rybelsus | $1,822 | $254,016180 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $648 | $141,136201 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,534 | $117,03596 claims |
| AmgenProlia | $779 | $106,22562 claims |
| Astellas Pharma US IncMyrbetriq | $483 | $90,850129 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $762 | $74,094108 claims |
| MerckJanuvia, Janumet | $381 | $39,61033 claims |
| Johnson & JohnsonXarelto | $205 | $37,37635 claims |
| AbbVieLinzess | $2,121 | $14,28914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Watsontown
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Alvin KingcadePhiladelphia$101K
- Jeffrey CameronWashington$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.